The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A Controlled Trial of Erenumab for Episodic Migraine
Open accessAbstract
BACKGROUND: We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine. METHODS: We randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 months. The primary end point was the change from baseline to months 4 through 6 in the mean number of migraine days per month. Secondary end points were a 50% or greater reduction in mean migraine days per month, change in the number of days of use of acute migraine-specific medication, and change in scores on the physical-impairment and everyday-activities domains of the Migraine Physical Function Impact Diary (scale transformed to 0 to 100, with higher scores representing greater migraine burden on functioning). RESULTS: A total of 955 patients underwent randomization: 317 were assigned to the 70-mg erenumab group, 319 to the 140-mg erenumab group, and 319 to the placebo group. The mean number of migraine days per month at baseline was 8.3 in the overall population; by months 4 through 6, the number of days was reduced by 3.2 in the 70-mg erenumab group and by 3.7 in the 140-mg erenumab group, as compared with 1.8 days in the placebo group (P<0.001 for each dose vs. placebo). A 50% or greater reduction in the mean number of migraine days per month was achieved for 43.3% of patients in the 70-mg erenumab group and 50.0% of patients in the 140-mg erenumab group, as compared with 26.6% in the placebo group (P<0.001 for each dose vs. placebo), and the number of days of use of acute migraine-specific medication was reduced by 1.1 days in the 70-mg erenumab group and by 1.6 days in the 140-mg erenumab group, as compared with 0.2 days in the placebo group (P<0.001 for each dose vs. placebo). Physical-impairment scores improved by 4.2 and 4.8 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 2.4 points in the placebo group (P<0.001 for each dose vs. placebo), and everyday-activities scores improved by 5.5 and 5.9 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 3.3 points in the placebo group (P<0.001 for each dose vs. placebo). The rates of adverse events were similar between erenumab and placebo. CONCLUSIONS: Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine-specific medication over a period of 6 months. The long-term safety and durability of the effect of erenumab require further study. (Funded by Amgen and Novartis; STRIVE ClinicalTrials.gov number, NCT02456740 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Migraine — Current Understanding and Treatment
Goadsby, P. J., Lipton, R. B., & Ferrari, M. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmra010917 · Cited by 1,918
Self-citationVasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,597
Self-citationCalcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
Olesen, J., Diener, H.-C., Husstedt, I. W., Goadsby, P. J., Hall, D., Meier, U., Pollentier, S., & Lesko, L. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030505 · Cited by 1,189
Self-citationGoadsby, P. J., & Edvinsson, L. (1993) · Annals of Neurology · doi:10.1002/ana.410330109 · Cited by 1,158
Self-citationCgrp May Play A Causative Role in Migraine
Lassen, L., Haderslev, P., Jacobsen, V., Iversen, H., Sperling, B., & Olesen, J. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00310.x · Cited by 1,027
Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30083-2 · Cited by 722
Self-citationBuse, D. C., Manack, A. N., Fanning, K. M., Serrano, D., Reed, M. L., Turkel, C. C., & Lipton, R. B. (2012) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2012.02223.x · Cited by 549
Ho, T. W., Ferrari, M. D., Dodick, D. W., Galet, V., Kost, J., Fan, X., Leibensperger, H., Froman, S., Assaid, C., Lines, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61626-8 · Cited by 531
CGRP and its receptors provide new insights into migraine pathophysiology
Ho, T. W., Edvinsson, L., & Goadsby, P. J. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.127 · Cited by 523
Self-citationAdherence to oral migraine-preventive medications among patients with chronic migraine
Hepp, Z., Dodick, D. W., Varon, S. F., Gillard, P., Hansen, R. N., & Devine, E. B. (2015) · Cephalalgia · doi:10.1177/0333102414547138 · Cited by 433
Dodick, D. W., Goadsby, P. J., Silberstein, S. D., Lipton, R. B., Olesen, J., Ashina, M., Wilks, K., Kudrow, D., Kroll, R., Kohrman, B., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70209-1 · Cited by 372
Self-citationDodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368
Self-citationSun, H., Dodick, D. W., Silberstein, S., Goadsby, P. J., Reuter, U., Ashina, M., Saper, J., Cady, R., Chon, Y., Dietrich, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00019-3 · Cited by 358
Self-citationGuidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults
Silberstein, S., Tfelt-Hansen, P., Dodick, D., Limmroth, V, Lipton, R., Pascual, J., Wang, S., & for the Task Force of the International Headache Society Clinical Trials Subcommittee (2008) · Cephalalgia · doi:10.1111/j.1468-2982.2008.01555.x · Cited by 303
Marcus, R., Goadsby, P. J., Dodick, D., Stock, D., Manos, G., & Fischer, T. Z. (2014) · Cephalalgia · doi:10.1177/0333102413500727 · Cited by 296
Self-citationBigal, M. E., Dodick, D. W., Rapoport, A. M., Silberstein, S. D., Ma, Y., Yang, R., Loupe, P. S., Burstein, R., Newman, L. C., & Lipton, R. B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00249-5 · Cited by 287
Hewitt, D. J., Aurora, S. K., Dodick, D. W., Goadsby, P. J., Ge, Y. (., Bachman, R., Taraborelli, D., Fan, X., Assaid, C., Lines, C., et al. (2011) · Cephalalgia · doi:10.1177/0333102411398399 · Cited by 263
Self-citationVoss, T., Lipton, R. B., Dodick, D. W., Dupre, N., Ge, J. Y., Bachman, R., Assaid, C., Aurora, S. K., & Michelson, D. (2016) · Cephalalgia · doi:10.1177/0333102416653233 · Cited by 247
Current practice and future directions in the prevention and acute management of migraine
Goadsby, P. J., & Sprenger, T. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70005-3 · Cited by 230
Self-citationRandomized, controlled trial of telcagepant for the acute treatment of migraine
Connor, K. M., Shapiro, R. E., Diener, H. C., Lucas, S., Kost, J., Fan, X., Fei, K., Assaid, C., Lines, C., & Ho, T. W. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b87942 · Cited by 217
Diener, H.-C., Barbanti, P., Dahlöf, C., Reuter, U., Habeck, J., & Podhorna, J. (2011) · Cephalalgia · doi:10.1177/0333102410388435 · Cited by 214
Self-citationShi, L., Lehto, S. G., Zhu, D. X. D., Sun, H., Zhang, J., Smith, B. P., Immke, D. C., Wild, K. D., & Xu, C. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227793 · Cited by 208
Lipton, R. B., Manack Adams, A., Buse, D. C., Fanning, K. M., & Reed, M. L. (2016) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12878 · Cited by 191
Charles, A. C. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32836085f4 · Cited by 105
Adelman, J. U., Freitag, F. G., Láinez, M. J. A., Shi, Y., Ascher, S., Mao, L., Greenberg, S. J., & Hulihan, J. F. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00389.x · Cited by 52
Cited by
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0003-1 · Cited by 999
Ashina, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1915327 · Cited by 816
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
American Headache Society (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13456 · Cited by 567
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
Dodick, D. W., Ashina, M., Brandes, J. L., Kudrow, D., Lanteri-Minet, M., Osipova, V., Palmer, K., Picard, H., Mikol, D. D., & Lenz, R. A. (2018) · Cephalalgia · doi:10.1177/0333102418759786 · Cited by 566
Self-citation
Metadata
- Authors
- Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-30
- Volume
- 377
- Issue
- 22
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2770965214
- Cited by
- 928
- References
- 27
- FWCI
- 70.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.